Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
114
datasets available to search
ShareScore release 0.9.0
Dataset results
114 results for “PD-L1 expression;”
Evaluation of PD-L1 expression in vulvar cancer
<p><strong>background & Aims: </strong>Vulvar cancer accounts for about 4% of all female genital malignancies. Squamous cell carcinoma is the most common histological type.PD-L1 is a membranous protein of nucleated cells. By binding to its PD-1 receptor, PD-L1 inactivates T lymphocytes. It plays a key role in the treatment of some cancers. Our aims were to study the expression profile of PD-L1 in vulvar cancer by immunohistochemistry and to correlate its expression with survival rates. <strong>Methods:</strong> A retrospective study was conducted in the Pathology Department of Saleh Azaiez Institute, involving 55 patients followed for vulvar cancer over a period of 13 years from January 2008 to December 2021. Clinicopathologic data were collected from medical records and pathology reports. Immunohistochemical analysis was performed using an automaton (Leica Biosystems™). <strong>Results:</strong> PD-L1 expression in vulvar squamous cell carcinoma was observed in 44% of cases. This expression was noted in 11% of cases at the level of lymphocytes whose dissection was negative in all cases with a maximum tumor size of 40 mm. PDL1 was expressed in tumor cells in 33% of cases where there was a positive inguinal dissection in 22% of cases and a maximum tumor size of 90 mm. <strong>Conclusions:</strong> The immune checkpoint inhibitor PD-1/PD-L1 seems to have an important prognostic effect on the development of some cancers (breast cancer, lymphoma). Indeed, the expression of PD-L1 in tumors is often considered a factor of poor prognosis due to its immunosuppressive activity in tumor tissues. Many studies have attempted to determine the prognostic factors of vulvar cancer in order to optimize therapeutic management. PD-L1 expression in vulvar squamous cell carcinoma has not been studied before, hence the interest of our study which suggested, as in the literature, a prognostic role for this protein.</p>
Metabolomic analysis of cultured TRAMP-C2 cells in the presence or absence of PD-L1 expression
<p>The interaction between the immune inhibitory receptor PD-1 and its ligand PD-L1 is a critical mechanism for altering immune responses, especially during chronic antigen exposures such as cancer. While much research has focused on the PD-1 receptor, recent evidence suggests that PD-L1 can have cell-intrinsic effects in cancer and immune cells. These functions are distinct from its ability to bind and trigger PD-1 activity and are notable given that PD-L1 is widely expressed in mammals. One such cell-intrinsic function is the modulation of cellular metabolism, including regulation of mTOR activity and glycolysis. As part of our investigation into PD-L1 function, we analyzed the metabolome of cultured mouse prostate cancer cells (TRAMP-C2) expressing PD-L1 or with PD-L1 deleted via CRISPR/Cas9. We quantified 186 water-soluble metabolites from TRAMP-C2 cells expressing PD-L1 or not to better understand what metabolic pathways and processes are regulated by PD-L1 expression/activity. We found a broad range of differentially abundant metabolites, most notably a decreased abundance of glycolytic metabolites when PD-L1 expression is knocked out. In our manuscript, we show that this has a functional outcome on viral infection and cytokine signaling.</p>
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
ClinicalTrials.gov study NCT02999477. IPD Sharing: NO. Countries: 1. Publications: 2.
M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT03631706. IPD Sharing: YES. Countries: 18. Publications: 3.
Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study
ClinicalTrials.gov study NCT07331701. IPD Sharing: NO. Countries: 1. Publications: 7.
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally
ClinicalTrials.gov study NCT02352948. IPD Sharing: YES. Countries: 26. Publications: 2.
Metabolomic analysis of cultured TRAMP-C2 cells in the presence or absence of PD-L1 expression
Open the record for dataset details and reuse information.
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
ClinicalTrials.gov study NCT06357533. IPD Sharing: YES. Countries: 21. Publications: 0.
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1%
ClinicalTrials.gov study NCT05445843. IPD Sharing: YES. Countries: 19. Publications: 0.
99mTc/68Ga Labeled Anti-PD-L1 sdAb in Assessment of PD-L1 Expression in NSCLC
ClinicalTrials.gov study NCT02978196. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Expression of Programmed Death Ligand-1 (PD-L1) in Nasopharyngeal and Hyypopharyngeal Carcinoma
ClinicalTrials.gov study NCT05595265. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.
PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma
ClinicalTrials.gov study NCT03989297. IPD Sharing: Not stated. Countries: 1. Publications: 1.
PD-L1 Expression in Cancer (PECan Study).
ClinicalTrials.gov study NCT04436406. IPD Sharing: NO. Countries: 1. Publications: 3.
A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT03258788. IPD Sharing: Not stated. Countries: 1. Publications: 0.
PD-L1 Expression in Lung Cancer
ClinicalTrials.gov study NCT04992715. IPD Sharing: NO. Countries: 1. Publications: 4.
Novel Strategy to Regulate PD-L1 Expression and Enhance Anti-Tumor Effect
<p>Figs source data</p> <p> </p>
Novel Strategy to Regulate PD-L1 Expression and Enhance Anti-Tumor Effect
<p>Figs source dat</p>
Inhibition of the α4β1 integrin activity by small Tellurium molecules Regulates PD-L1 Expression and Enhances Anti-Tumor Effect
<p>Figs source data</p>
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP
ClinicalTrials.gov study NCT05280626. IPD Sharing: NO. Countries: 0. Publications: 6.
The WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape
GEO Series GSE178677. Mus musculus. 12 samples. Type: Genome binding/occupancy profiling by high throughput sequencing; Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.